Patients with psoriasis (PsO) and psoriatic arthritis (PsA) frequently present with obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, all of which worsen outcomes and reduce treatment response. Dietary interventions represent one strategy to address this interplay, targeting the microbiome, metabolome, and joint inflammation. Antiinflammatory and hypocaloric diets improve symptoms and metabolic profiles. In parallel, glucagon-like peptide 1 receptor agonists (GLP-1RAs), originally approved for T2DM and obesity, have emerged as promising agents with both metabolic and immunomodulatory effects. Early reports in PsO and PsA suggest potential benefit, though evidence remains preliminary and based on small, heterogeneous studies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Patient Research Partner (PRP) initiative highlights that people living with psoriatic disease (PsD) value holistic strategies that address comorbidities, improve quality of life, and support shared decision making. Most patients attempted lifestyle changes, yet common barriers included fatigue, lack of motivation, and absence of specific recommendations from treating physicians. Together, dietary approaches, GLP-1RAs, and patient-informed priorities underscore the potential of multidisciplinary, collaborative care to optimize outcomes in PsD.
Marchionni et al. (Tue,) studied this question.